KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -$5.7 million.

  • Emergent BioSolutions' Free Cash Flow fell 103.85% to -$5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 98.99%. This contributed to the annual value of $35.8 million for FY2024, which is 113.88% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Free Cash Flow of -$5.7 million as of Q3 2025, which was down 105.51% from $103.5 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Free Cash Flow peaked at $282.3 million during Q4 2021, and registered a low of -$253.4 million during Q3 2022.
  • For the 3-year period, Emergent BioSolutions' Free Cash Flow averaged around -$12.6 million, with its median value being -$5.7 million (2025).
  • As far as peak fluctuations go, Emergent BioSolutions' Free Cash Flow tumbled by 558.18% in 2022, and later soared by 212.03% in 2024.
  • Emergent BioSolutions' Free Cash Flow (Quarterly) stood at $282.3 million in 2021, then slumped by 67.13% to $92.8 million in 2022, then plummeted by 77.69% to $20.7 million in 2023, then plummeted by 494.20% to -$81.6 million in 2024, then crashed by 103.85% to -$5.7 million in 2025.
  • Its last three reported values are -$5.7 million in Q3 2025, $103.5 million for Q2 2025, and -$14.8 million during Q1 2025.